Literature DB >> 31029668

Three-year Active Surveillance Outcomes in a Contemporary Community Urology Cohort in the United States.

Jeremy B Shelton1, Thomas A Paivanas2, Phil Buffington3, Stephen R Ruyle4, Edward S Cohen5, Richard Natale6, Bryan Mehlhaff7, Ronald Suh8, Timothy J Bradford9, Alec S Koo10, Lorna Kwan11, Neal Shore12.   

Abstract

OBJECTIVES: To determine the 3-year outcomes of men with prostate cancer managed with active surveillance (AS) in a cohort of geographically diverse community-based urology practices. AS is the management of choice for a majority of men with lower risk prostate cancer.1,2,3 Little is known about the contemporary "real-world" follow-up and adherence rates in the most common setting of urologic care, community (private) practice.4
METHODS: We retrospectively evaluated outcomes for men diagnosed between January 1, 2013 and May 31, 2014 with National Comprehensive Cancer Network (NCCN) very low, low and intermediate risk prostate cancer who selected AS in 9 large community urology practices. We used univariate and multivariate analyses to describe associations between race, age, insurance status, family history, comorbidity, clinical stage, Gleason score, NCCN risk-group, and PSA density with discontinuation of AS.
RESULTS: Five hundred and forty-eight men on AS were followed for a median of 3.35 years. 89% (492) continued to follow-up with diagnosing practice. 32% (171) discontinued AS. On multivariate analysis, increasing NCCN risk classification (Hazard ratio [HR] 1.65, P = 0.02 and HR 2.09, P < 0.01 for low and intermediate risk vs very low risk) was significantly associated with discontinuation. Among those who discontinued AS, surgery and radiation were utilized equally (47% and 53%, respectively, P = 0.48).
CONCLUSION: In this community-based cohort of men on AS, a minority was lost to follow-up and adherence to AS was similar to other reports. Disease characteristics more than sociodemographic characteristics correlated with adherence to AS, while surgery and radiotherapy were utilized equally among those discontinuing AS, both suggesting guideline concordant practice of medicine. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2019        PMID: 31029668     DOI: 10.1016/j.urology.2019.04.017

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  3 in total

1.  Active surveillance before radiotherapy: Outcome and predictive factors for multiple biopsies before treatment.

Authors:  Alexandre Alcaidinho; Guila Delouya; Jean-Paul Bahary; Fred Saad; Daniel Taussky
Journal:  Can Urol Assoc J       Date:  2021-01       Impact factor: 1.862

Review 2.  Progression on active surveillance for prostate cancer in Black men: a systematic review and meta-analysis.

Authors:  Hari T Vigneswaran; Luke Mittelstaedt; Alessio Crippa; Martin Eklund; Adriana Vidal; Stephen J Freedland; Michael R Abern
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-07-08       Impact factor: 5.554

Review 3.  Active Surveillance in Intermediate-Risk Prostate Cancer: A Review of the Current Data.

Authors:  Leandro Blas; Masaki Shiota; Masatoshi Eto
Journal:  Cancers (Basel)       Date:  2022-08-27       Impact factor: 6.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.